15% OFF Retatrutide – 60mg/vial — Research Use Only
Retatrutide is an investigational triple agonist targeting the GIP, GLP-1 and glucagon receptors. It is not approved by FDA or any other regulator and is supplied strictly for laboratory research and identification purposes. Not for human or veterinary use.
Availability: In stock
3–4 vials — 5% off · 5–9 vials — 10% off · 10+ vials — 15% off
Applied automatically in the cart. Combines with a discount code up to 20% off in total, and stacks on top of the subscription discount.
Research Disclaimer: All products currently listed on this site are for research purposes only.
Independent lab result · batch PTW-Reta60-2608-001
Retatrutide 60mg. Tested by Janoshik Analytical (task #239839), analysis conducted 7 Oct 2026. The sample was pulled from our own stock, submitted and paid for by Portal to Wellness, and the report names us as the client.
- Identity: retatrutide, confirmed by blind test
- Measured content: 64.59 mg per vial (labelled 60 mg)
- Purity: 99.725% (HPLC)
View and verify the full report on Janoshik’s site →
This result applies to batch PTW-Reta60-2608-001, the batch currently shipping. The batch number is printed on the vial label. See all published results on our Lab Testing & Verification page.
Retatrutide (LY3437943) is a novel unimolecular triple agonist that simultaneously engages three receptor pathways: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple-receptor mechanism distinguishes it from dual agonists and single-agonist compounds currently available for research.
Development Stage
Retatrutide is an investigational compound in Phase 3 clinical development. Sponsor-reported trial results are summarised with sources in the Research Library rather than here — product pages on this site do not carry clinical efficacy data.
Retatrutide Phase 3 TRIUMPH-1 results, reviewed →
Regulatory Status
Retatrutide is not approved by FDA or any regulatory agency for any use. It is not a component of any approved drug and is not eligible for pharmacy compounding under section 503A or 503B of the FD&C Act. Supplied for research use only — not for human or veterinary use.
Research Library
- GLP-1 Receptor Agonists and Biological Aging: What the Research Shows
- Injectable vs. Oral GLP-1: What Researchers Need to Know
- Retatrutide Phase 3 TRIUMPH-1 Results: Key Findings for Researchers
- Retatrutide vs. Tirzepatide: What the Phase 3 TRIUMPH-1 Data Shows Researchers
- Preserving Lean Mass During GLP-1 Research: What the SEMALEAN Data Showed
- GLP-1 Prior Authorization Data
- Retatrutide Expanded Access, Explained
- Is Retatrutide Legal in 2026? FDA Status and Lilly Lawsuits
- GLP-1 Cancer Risk: What Trials Show
- GLP-1 Mood Research: What Trials Show
- Real-World GLP-1 Outcomes vs Trial Results
For research use only. Not intended for human or veterinary use.
Compare Retatrutide Sizes
All three are the same compound at different vial sizes. Price-per-mg drops as size increases.
| Product | Concentration | Price | Price / mg |
|---|---|---|---|
| Retatrutide 30mg | 30mg/vial | $169.00 | $5.63 |
| Retatrutide 50mg | 50mg/vial | $199.00 | $3.98 |
| Retatrutide 60mgLowest $/mg | 60mg/vial | $219.00 | $3.65 |
- Processing: Orders ship within 1–2 business days
- Domestic delivery: 3–5 business days via USPS Priority / UPS Ground
- Free shipping on orders over $100
- Temperature handling: Cold-chain packaging available on request for lyophilized peptides
- Tracking: Emailed automatically at time of dispatch
- Store lyophilized (dry) peptides at −4 °F for long-term stability
- Protect from light and moisture at all times
- Do not freeze
- Where the Storage row in the product specification above differs, follow the specification
Pairs Well With
Related research products
Alfredo Loera (verified owner) –
Excellent